Combined with the findings that the decrease of plasma GDF-11 level was correlated to the severity of psychotic symptoms and cognitive impairments, we speculate that the population difference of plasma GDF-11 is more likely to be from to the disease itself, rather than to the secondary influence of drug therapy. This evidence concerns the gene GDF11 and Cognitive impairment.